"Using an antibody reactive with complementary PR3 protein, produced in the laboratory, we analyzed protein pools removed from the patients' plasma during plasma exchange therapy to identify any ...

Methods to improve protein stability are important in the biopharmaceutical industry. Here, the authors describe a high-throughput screen to increase protein thermostability and identify ...

The addition of the Gyrolab Generic Rodent ADA Kit Reagents to our portfolio enhances our offering of ready-to-use kits and solutions for use in drug screening and preclinical development.

Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented:"The new Gyrolab Generic Anti-AAV Kit is tailored to meet customer needs in the ...

The results showed autoantibodies to a complementary protein that, to the researchers’ surprise, turned out to be plasminogena protein. In the research, 22% of the patients with PR3 ANCA ...

UPPSALA, Sweden---- Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction ...

Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: “The introduction of the Gyrolab Generic Cyno ADA Kit Reagents is another valuable ...

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers, today announced its Gyrolab® Generic Anti-Adeno Associated Virus ...

Gyros Protein Technologies AB, announced the introduction of Gyrolab ® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent ...

The new ready-to-use kit reagents streamline pre-clinical development of antibody-based therapeutics, enabling immunogenicity screening of drug candidates without the need for drug-specific ADA ...